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The blood-brain barrier (BBB) is a multicellular vascular structure that separates the central 65 nervous system (CNS) from peripheral blood circulation. The BBB comprises endothelial 66 cells that have continuous intercellular tight junction, regulates influx and efflux transport, 67 and protects the CNS from toxins and pathogens. This barrier also limits the cells and 68 macromolecules that enter into cerebral circulation. However, multiple studies demonstrated 69 that this strictly regulated barrier is compromised in several CNS diseases; extravasation of 70 lymphocytes and serum proteins through the BBB can occur in patients who have 71 inflammation, an infection, or both [1] [2] [3] . 72 B cells contribute to the pathogenesis of CNS autoimmune diseases, which is 73 indicated by local production of antibodies within the CNS [4, 5] , by damage of the CNS 74 tissue by antibody and complement [6] and by the therapeutic effects of plasmapheresis or 75 anti-CD20 monoclonal antibody [7, 8] . Flach et al. reported that myelin-specific antibodies overnight at around pH 8 and at 37 ºC. Trifluoroacetic acid (10%, Nacalai Tesque, Kyoto, 143 Japan) was added to stop the digestion, and the supernatant was recovered. Finally, the 144 volume of this mixture was reduced to approximately 80 μl using reduced pressure. The 
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Using immune complexome analysis, we identified 176 IC-associated antigens in CSF 172 samples from 1) patients with one of four CNS autoimmune diseases, 2) patients with AD or 173 Hashimoto's encephalopathy, or 3) healthy donors. In supplementary table 1, we express how 174 often each antigen were detected in patients with a certain disease as a percentage of the total 175 number of patients with the disease. Representative total ion chromatogram in immune 176 complexome analysis of CSF sample is shown in Fig. 1 with that of serum sample. 177 To determine whether immune complexome analysis was distinct from conventional 178 CSF proteome analysis, we assessed the overlaps among the 176 IC-associated antigens 179 identified in CSF, the CSF proteome, and the plasma proteome ( Fig. 2) . Here, we used the 180 CSF proteome characterized from the proteins comprehensively detected in healthy 181 individuals who had no neurologic symptoms [32], while we used the plasma proteome 182 published by Human Proteome Organization [33] . Initially, we compared our dataset (176 183 protein antigens) with the CSF proteome dataset (2628 proteins) and found that only 26 of the protein antigens were also in the CSF proteome. Next, we compared the 176 IC-associated 185 CSF antigens with the 3020 proteins in the plasma proteome dataset and found that only 18 186 proteins were in both groups. Also, 8 antigens were found in all three groups; 140 of the 176 187 antigens were found to be exclusively detected by our method. Specifically, apolipoproteins, 188 complements, dermcidin, fibulin and desmplakin were detected in all three groups; 189 hemoglobins and uncharacterized proteins were detected in both the CSF immune were also included in the CSF proteome, 6 (23%) were among the previously reported (suprabasin isoform 1 precursor and Isoform 7 of Nesprin-1) were 100% specific to NPSLE, 206 and three (Isoform B of Fibulin-1, Isoform 10 of Fibronectin, and Isoform 12 of Fibronectin) 207 were 100% specific to NMO. Of the disease-specific antigens, IC-associated suprabasin 208 (SBSN) were found in 9 of 26 NPSLE patients (35% (9/26); 95% CI, 17%-57%) and 209 appeared more sensitive than the others (Isoform 7 of Nesprin-1, 7.7% (2/26); Isoform B of 210 Fibulin-1, Isoform 10 of Fibronectin and Isoform 12 of Fibronectin, 13% (2/16)). The 211 antigens selectively detected in one or two disease groups are summarized with sensitivity 212 and specificity in Table 1 . 15-17, 19, 20] ; however, these studies did not comprehensively identify the antigens that form 228 ICs with the corresponding antibodies. 229 Here, we describe the first comprehensive identification of IC-associated antigens 230 in CSF ( Supplementary table 1 ). We used the CSF proteome comprising 2628 proteins . Notably, only 15% of the 176 protein antigens we identified 239 were also in such CSF proteome dataset; therefore, immune complexome analysis selectively 240 recovered ICs in CSF and identified the constituent antigens, and our method can be 241 distinguished from the conventional CSF proteome analysis. On the other hand, some 242 peripheral blood proteins can cross the BBB and enter cerebral circulation by a simple 243 diffusion mechanism as a function of their molecular size. It had been generally believed that 244 the majority of proteins in CSF originate from peripheral blood [43] . However, Zougman et al. 245 reported that the CSF proteome has only partial overlap with the plasma proteome and that 246 the CSF proteome derives from local protein sources not just from blood circulation [39] . In our analysis, only 18 of 176 IC-associated antigens were also found in the plasma proteins. 248 This indicates that the BBB limits peripheral ICs enter the brain, which was confirmed by our 249 comparison of total ion chromatograms of CSF and serum samples that had been subject to 250 immune complexome analysis (Fig. 1) . Our observation supports that characteristic and 251 substantial intrathecal humoral immune responses occur in infectious and CNS autoimmune 252 diseases in which local B cells contribute to CSF autoantibody production [5] . Our method 253 may be useful to in vivo screening the target antigens of oligoclonal band antibodies that are 254 locally produced by clonally expanded antigen-experienced B cells [5] because the method is 255 different from conventional in vitro antigen screening arrays using recombinant proteins. 256 Most IC-associated antigens (140 of 176) in the CSF immune complexome were found to be 257 exclusively detected by the immune complexome analysis. In the comparison between 140 258 antigens specific to the CSF immune complexome and previously-reported disease-associated 259 CSF proteins, only a few (6 antigens) immune complexome-specific antigens were among the 260 previously-reported disease-associated CSF proteins. This indicated that protein upregulation 261 in CSF rarely leads to immunological responses producing ICs, and the other factors, such as 262 mutation and misfold, may contribute to such responses. These findings also indicated that 263 immune complexome analysis identified a group of proteins that was distinct from screening 264 methods for disease-associated proteins in CSF. This is because selective enrichment for ICs 265 increases sensitivity for IC-derived antigens that would otherwise be masked by whole CSF 266 proteome. The specificity indicated that our method explores a new path for discovery of 267 disease-specific or pathogen-specific markers in CSF. However, our method is a screening method for discovering disease-associated immune 277 complex antigens. The sensitivity of individual disease-specific antigens may be improved by 278 developing ELISA methods that each detects a certain IC with high specificity and sensitivity 279 [47]; if such ELISAs were developed, these disease-specific antigens may become promising 280 diagnostic or pathogenic biomarkers. On the other hand, immune complexome analysis of 281 diseased tissue is more straightforward to understand the antigenicity. However, it is difficult 282 to recover the tissue from CNS; therefore, immune complexome analysis of patient's CSF is 283 useful to screening the CNS autoimmune disease-specific IC antigens. Furthermore, if the 284 epitope peptides of the antigens were identified, we can expand the study to develop an 285 epitope-targeted therapy, which concludes the clinical and therapeutic benefit of the antigen. 286 SBSN was initially identified as an epidermal differentiation marker [48] ; it was 287 then reported to be epigenetically depressed in lung cancer [49, 50] . Our follow-up 288 experiments showed that an anti-SBSN antibody was highly expressed in NPSLE patients 289 compared to SLE and MS, and induced interleukin-6 production with lipopolysaccharide 290 stimulation in astrocytes [51] . Additionally, microarray data showed that the senescence, 291 autophagy pathways and TGF-β signaling were significantly changed in astrocytes exposed to Of the CNS autoimmune diseases investigated in this study, only NMO has been 300 associated with a specific biomarker; reportedly, an autoantibody (anti-aquaporin-4 antibody) 301 can distinguish NMO from the other three diseases, and especially from MS [52, 53] . 302 Although all the NMO patients enrolled in this study were positive for anti-aquaporin-4 303 antibody, immune complexome analysis did not identify aquaporin-4 as an IC-associated 304 antigen in CSF; IC-associated aquaporin-4 may be absent from CSF samples because 305 aquaporin-4 is anchored within astrocyte membranes. Aquaporin-4 is anchored to astrocyte 306 foot process membranes by the dystroglycan complex, and it faces the abluminal surface of 307 blood vessels; moreover, aquaporin-4-antibody binding is followed by complement activation 308 [54] . 309 General proteomic approaches used for diagnostic or pathogenic biomarkers 310 discovery both identify and quantify proteins; however, there are often too many proteins that 311 are differentially expressed between disease and control groups to be validated as biomarkers. 312 In fact, these general approaches have delivered few if any useful diagnostic or pathogenic 313 biomarker to clinical setting. In contrast, our method found the antigens that were detected 314 only in a disease group and not in a control group. Therefore, naturally only a few antigens 315 would be examined in subsequent validation studies. Our method includes the risk that some 316 useful biomarkers are missed because they are detected in both groups and only expression 317 levels differ between groups. However, the antigens specifically detected in a disease group 318 are thought to be more promising candidates for biomarkers. Based on these observations, we 319 suggest that immune complexome analysis is a promising approach to screening for 320 diagnostic or pathogenic IC biomarkers in CSF.
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Conclusions
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This report is the first to comprehensively identify the antigens incorporated into ICs in CSF. 324 This group of antigens has limited overlap with the CSF proteome or the plasma proteome; 325 therefore, our method, which focused on ICs, explores a new avenue for discovery of CSF comprises 2628 proteins, and the HUPO plasma proteome dataset comprises 3020 proteins [33] ; both were used as reference datasets. Integrator complex subunit 4-like protein 2 IPI00102193.5
